CNS demyelination and quadrivalent HPV vaccination

I. Sutton, R. Lahoria, I. L. Tan, P. Clouston, Michael H. Barnett*

*Corresponding author for this work

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Vaccination is generally considered safe in patients with multiple sclerosis (MS). We report five patients who presented with multifocal or atypical demyelinating syndromes within 21 days of immunization with the quadrivalent human papilloma virus (HPV) vaccine, Gardasil®. Although the target population for vaccination, young females, has an inherently high risk for MS, the temporal association with demyelinating events in these cases may be explained by the potent immuno-stimulatory properties of HPV virus-like particles which comprise the vaccine. A prospective case-control study of patients with MS or clinically isolated demyelinating syndromes receiving the Gardasil® vaccine may provide relevant safety data in this population.

Original languageEnglish
Pages (from-to)116-119
Number of pages4
JournalMultiple Sclerosis
Volume15
Issue number1
DOIs
Publication statusPublished - 2009
Externally publishedYes

Keywords

  • Demyelination
  • Human papillomavirus
  • Multiple sclerosis
  • Vaccination

Fingerprint Dive into the research topics of 'CNS demyelination and quadrivalent HPV vaccination'. Together they form a unique fingerprint.

  • Cite this

    Sutton, I., Lahoria, R., Tan, I. L., Clouston, P., & Barnett, M. H. (2009). CNS demyelination and quadrivalent HPV vaccination. Multiple Sclerosis, 15(1), 116-119. https://doi.org/10.1177/1352458508096868